1 We have investigated the effects of RP 73401, a novel, potent and highly selective cyclic nucleotide phosphodiesterase (PDE) type IV inhibitor, in guinea-pig and rat models of bronchoconstriction and allergic inflammation. In some models, the effects of RP 73401 have been compared with those of the standard PDE type IV inhibitor, rolipram. 2 RP 73401 (0.4-400 fg kg-', intratracheally (i.t.) on lactose) inhibited antigen-induced bronchospasm in previously sensitized conscious guinea-pigs (ID": 7 ± 1 gg kg-') and in anaesthetized rats (ID5: 100 ± 25 fig kg-) . Rolipram inhibited the antigen-induced bronchospasm in guinea-pigs with an ID.V of 5 ± 1 ftg kg-'. In guinea-pig bronchoalveolar lavage (BAL) fluid, total inflammatory cell and eosinophil numbers were reduced by RP 73401 (ID50s: 3.9 ± 0.8 jig kg-' and 3.2 ± 0.7 jig kg-', respectively). In the rat, inflammatory cell numbers are less affected. Only the highest dose of RP 73401 (400 pg kg-') significantly inhibited eosinophil influx (41 ± 16% inhibition). 3 RP 73401 (0.02-100 jig kg-', i.v.) inhibited PAF-induced bronchial hyperreactivity to bombesin in the anaesthetized guinea-pig (ID": 0.09 ± 0.03' gkg-') and inhibited (0.4-40 jig kg-', i.t.) histamineinduced airway microvascular leakage in the anaesthetized guinea-pig by approximately 60% at all doses.
Introduction
At least five different cyclic nucleotide phosphodiesterase (PDE) isoenzymes have now been identified on the basis of their functional characteristics such as substrate specificity and susceptibility to selective inhibitors (Beavo & Reifsnyder, 1990 ). The realization that there are differences in the relative functional importance of the PDE isoenzymes in specific cell types has fuelled the search for isoenzyme-selective PDE inhibitors which can be targeted to the cells implicated in the pathophysiology of asthma (Torphy & Undem, 1991; Giembycz & Dent, 1992; .
Granulocytes, mononuclear cells and mast cells/basophils contain principally the PDE type IV isoenzyme. Inhibition of this enzyme is associated with increased intracellular adenosine 3':5'-cyclic monophosphate (cyclic AMP) and suppression of cell activity (Torphy & Undem, 1991; Author for correspondence. Dent, 1992; . Although human airways smooth muscle contains at least five isoenzyme families (see and references therein), the PDE III and PDE IV isoenzymes are functionally the most important as modulators of contractility (De Boer et al., 1992; Qian et al., 1993) . In animal studies the functional profile of PDE isoenzymes in airways smooth muscle preparations both in vitro and in vivo appears similar to that in human tissue .
RP 73401 (3-cyclopentyloxy-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide) is a novel, highly selective and very potent PDE type IV inhibitor Ashton et al., 1994) . PDE type IV isolated from various cell types is inhibited by RP 73401 with an IC5o of about 1 nM and it displays at least a 19,000 fold selectivity compared with the other PDE isoenzymes (Ashton et al., 1994; Souness et al., 1994b) . We have now characterized the airways smooth muscle relaxant and anti-inflammatory effects of RP 73401 in the guinea-pig and rat. In some models, we have compared the effects of RP 73401 with those of the standard PDE type IV inhibitor rolipram. This study demonstrates potent inhibitory effects on a range of bronchoconstrictor and'inflammatory responses in the tracheobronchial tree by RP 73401 and indicates that this compound has potential as an anti-asthma agent.
Methods

Guinea-pig isolated trachea
Male, Dunkin-Hartley guinea-pigs (350-500 g) were killed by cervical dislocation and the, tracheas removed and placed in Krebs-Ringer bicarbonate (KRB) solution. The epithelium was removed by gently rubbing the luminal surface with a cotton swab. Transverse tracheal strips were prepared and suspended under an applied load of 2 g in 5 ml tissue baths containing KRB solution at 37°C gassed with 5% CO2 in 02
The load was determined from preliminary experiments (data not shown) to give maximum force of contraction in response to methacholine. The composition of the KRB was as follows (mM): NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, glucose 10.1. Changes in isometric force of contraction were measured with force-displacement transducers (Grass FT03) connected to a pen recorder (Lectromed Multitrace 8).
To examine the effects of RP 73401 on basal tone, tracheal tissues were equilibrated for 60 min, washing at 10 min intervals with KRB solution. Isoprenaline (2 pM) was then added to the baths to determine zero tone. The isoprenaline was subsequently washed from the tissues and when tone was fully recovered, the relaxant effects of RP 73401 were assessed following its cumulative addition.
To examine effects on spasmogen-induced increases in the force of contraction tissues were equilibrated as above but KRB solution containing indomethacin (5.6 gM) was used.
Tissues were contracted to an EC30 (concentration producing 30% maximal contraction) of histamine (0.49 jLM, 0.94 ± 0.11 g), methacholine (0.10 gM, 0.82 ± 0.09 g) or leukotriene D4 (LTD4) (0.41 nM, 0.63 ± 0.04 g). Contractile responses to all agonists remained stable over the time-course of the experiment. When the contractile response to each agonist had plateaued, RP 73401 was added cumulatively. The vehicle for RP 73401 (dimethylsulphoxide, DMSO, 0.1%) produced less than 10% reduction in maintained force of contraction.
Responses to RP 73401 (mean ± s.e.mean from n animals) are expressed as % inhibition of spasmogen-induced contraction or % reduction in basal tone where appropriate. EC50 values (basal tone) or IC50 (precontracted tissues) were calculated by linear regression and are presented as geometric means with 95% confidence limits.
Spasmogen-induced bronchospasm in the anaesthetized guinea-pig Male, Dunkin-Hartley guinea-pigs (350-450 g) were anaesthetized with sodium pentobarbitone (60mg kg-', i.p.). The trachea was cannulated to allow mechanical ventilation (Harvard 683 rodent ventilator) at 60 strokes min-' with a stroke volume of 1 ml 00 g-'. Pulmonary inflation pressure (PIP) was measured with a Druck (model PDCR75) pressure transducer connected to a side arm from the tracheal cannula. Blood pressure was measured by a second pressure transducer connected to a cannula tied into the left carotid artery. Heart rate was derived from the blood pressure signal. PIP, blood pressure and heart rate were recorded on a Lectromed (Multitrace 8) pen recorder. A cannula was tied into the right jugular vein to allow administration of spasmogen solutions in saline. RP 73401 or rolipram (4-100Ftg kg-') were administered as a dry powder formulation (particle size, 4-8 pm) on lactose. A bolus (10mgkg-') dose was blown from a tube into the airways by a plastic bulb (Underwood et al., 1991; . Vehicle control animals received lactose carrier (1Omg kg-') alone. We have shown (data on file) that a uniform distribution of drug throughout the lung occurs following administration as a dry powder.
Spasmogens (histamine, methacholine or LTD4) were administered (i.v. bolus) at 6 min intervals and the dose titrated so that each produced an increase in PIP equivalent to about 60% of the maximum obtained by manually occluding the tracheal cannula. After two stable responses had been obtained, RP 73401 or rolipram were administered into the airways 1 min before the next dose of spasmogen. Administration of spasmogen was continued at 6 min intervals until responses had returned to pretreatment amplitude or for a maximum of 48 min. Each animal received only a single dose of the PDE inhibitor. Results are expressed as percentage inhibition (mean ± s.e.mean) of bronchospasm and duration of action (min). The ID50 (the dose causing 50% inhibition of bronchospasm) in each case was calculated by linear regression.
Antigen-induced bronchospasm in vivo
Guinea-pigs were sensitized (i.p.) with ovalbumin (10 Ag) and aluminium hydroxide (100 mg) in saline (1 ml). After 21-28 days, sensitization was confirmed by the intradermal injection of albumin (25 gd of 200 pg ml-') into the dorsal surface of the left ear. Animals not responding with marked erythema and oedema, maximal after 20-40 min, were excluded from the study. Sensitized animals were used 7-14 days later.
RP 73401 or rolipram (0.4-400 jig kg-') were administered intratracheally (i.t.). To facilitate dosing, animals were briefly anaesthetized with halothane (4% in oxygen) and placed in a dorsal recumbent position with the head elevated at an angle of 45°. A blunt-ended metal tube (external diameter 1.5 mm) was gently inserted through the larynx into the trachea. A bolus (10 mg kg-) of the dry powder formulation was blown from a tube into the airways as above. The dosing procedure took approximately 10 s, after which the animal rapidly recovered from anaesthesia. Vehicle control animals received lactose carrier (10 mg kg-') alone. Untreated control animals were not anaesthetized or dosed. Thirty min after administration of a PDE inhibitor or lactose, animals received mepyramine maleate (30 mg kg-', i.p.) to protect against fatal anaphylaxis during antigen challenge; 50 min after administration of a PDE inhibitor, animals were placed in a whole body, double chamber plethysmograph to allow measurement of specific airway resistance (sRaw) by a method modified from that described by Pennock et al. (1979) . A Buxco (model LS-14) respiratory mechanics analyser was used to measure the phase shift between nasal and thoracic air flows and compute sR1w on a breath by breath basis. A bias flow of air (600 ml min-') was maintained through the nasal chamber to ensure a constant supply of fresh air to the animal. This flow was subtracted by the respiratory mechanics analyser from its calculations.
Sixty min after administration of RP 73401 or rolipram, animals were challenged by exposure for 5 min to an aerosol of ovalbumin, generated from a 20 mg ml-' solution in saline by a nebulizer (deVilbiss Pulmosonic) and passed through the nasal chamber by an air pump operating at a flow rate of 121 min'. The mean sR,, was calculated for the 5 min period immediately before antigen challenge (baseline measurement) and for 3 consecutive 5 min periods after challenge. Histamine-induced microvascular leakage in the anaesthetized guinea-pig
Measurements of microvascular leakage (MVL) in guineapigs (400-500 g), anaesthetized with xylazine (0.8 mg kg', s.c.) and ketamine (3 mg kg-', s.c.), were made as previously described . RP 73401 (0.4-40 jig kg-') was administered as a dry powder as for the cell influx studies. A fine bore polythene cannula (external diameter 0.63 mm) was introduced into the trachea via the metal tube which was then withdrawn. The end of the cannula was positioned just below the larynx; 10 min after drug or vehicle administration, fluorescein isothiocyanate (FITC)-dextran (mol.wt. 150,000, 50 mg kg', i.v., marginal ear vein) was injected as a marker of plasma extravasation. After a further 10 min, histamine (60 nmol) was administered over a period of 2 min by superfusion of the airways via the polythene cannula. This dose was determined in preliminary studies to induce maximum MVL over basal levels without causing bronchospasm. Negative control animals received vehicle (saline, 0.02 ml min-') to establish basal leakage. Ten min after histamine or vehicle challenge, blood samples were removed by cardiac puncture and the animals were killed with sodium pentobarbitone (200 mg kg-', i.v.). The trachea and bronchi were removed and lavaged with phosphate-buffered saline (PBS, 3 x 1 ml). FITC content of tracheal tissue and lavage fluid was measured by agitating the samples for 15 h in PBS (2 ml) and assaying FITC content by fluorimetry (Perkin Elmer LS5B fluorescence spectrophotometer set with excitation and emission wavelengths of 480 and 520 nm respectively). FITC content was expressed as ngFITCmg-' tissue or ptgFITCm1-' lavage fluid. These values were calculated from a standard calibration curve of FITC-dextran concentration versus fluorescence intensity. Percentage inhibition of histamine-induced FITC extravasation was then calculated.
Effects on salbutamol-induced bronchodilatation in the anaesthetized guinea-pig Guinea-pigs were anaesthetized and prepared to allow stable responses to histamine to be obtained as described above. After 2 consecutive, reproducible responses RP 73401 (4 or 40 fig kg-, i.t. on lactose) was administered into the airways as previously described; 2 min later, animals similarly received salbutamol (2 or 10 tg kg-', i.t. on lactose) and 1 min later the next dose of histamine was given. Administration of histamine was continued at 6 min intervals until responses had returned to pretreatment amplitude. For each dose group, results (mean ± s.e.mean) were expressed as percentage inhibition of bronchospasm duration of action (min).
Cardiovascular effects of RP 73401
Rats (300± 50 g, Sprague-Dawley CD) were anaesthetized, ventilated and cannulated for blood pressure measurement as before. Drugs were administered (i.v.) into the jugular vein. Mean arterial blood pressure and heart rate were determined with a Modular Instruments Signal Processing Centre (MI2 system). Cardiovascular parameters were allowed to stabilize before drug administration. RP 73401 (0.01-0.25 mg kg-') was administered over 30s in a dose volume of 1 ml kg-' followed by a wash-in of saline (0.2 ml). The RP 73401 vehicle was polyethylene glycol 200/0.1 M HCL. Animals received only one dose of RP 73401. Cardiovascular parameters were measured before (baseline) and from 5 to 60 mn after drug treatment. Results are expressed as mean ± s.e.mean from n animals.
To assess cardiovascular effects following i.t. dosing in the anaesthetized guinea-pig, RP 73401 (ID50 against histamineinduced bronchospasm) was administered into the airways as before. Each animal received only a single dose of the PDE inhibitor. Baseline mean arterial blood pressure and heart rate were measured and expressed as group mean ± s.e.mean. The peak change in arterial blood pressure and heart rate in the 20 min period after dosing were each expressed as percent change from baseline values.
Drugs and solutions
Drugs used were: ovalbumin (chicken egg grade V), histamine diphosphate, methacholine chloride, salbutamol hemisulphate, bovine serum albumin, FITC- Table 2 . Both RP 73401 and rolipram were more potent as inhibitors of LTD4-induced bronchospasm than as inhibitors of either histamine or methacholine. In addition the degree of inhibition of LTD4-induced bronchospasm was greater than that seen with the other spasmogens. Since the PIP induced by each agonist was similar, the greater effect of RP 73401 and rolipram on the LTD4 response cannot be due to the smaller maximum contractile effects seen with this agent in vitro. RP 73401 and rolipram each had a similar duration of action against histamine (Figure 2b ) and methacholine ( Figure 3b ) but a markedly longer duration of action against LTD4 (Figure 4b ). Results are expressed as mean ± s.e.mean, n = 3-5. (Tables 3-5 ). In the guinea-pig, RP 73401 (4 and 40 jtg kg-') significantly inhibited eosinophil influx (Table 3) . Eosinophil numbers were also lower in guinea-pigs treated with rolipram (4 and 40 fig kg-') but the difference did not achieve statistical significance (Table 4 ). In the rat only the highest dose of RP 73401 (400 jig kg-') significantly inhibited (41 ± 16%) antigen-induced airway eosinophilia (Table 5 ). In each study the drug vehicle was without effect.
Antigen-induced bronchospasm
Aerosolized antigen caused an acute bronchospasm which peaked within 15 min in conscious guinea-pigs. SRaw increased from 4.7 ± 0.8 to 24.5 ± 2.9 ml cmH2O ' in vehicle control animals. RP 73401 and rolipram, but not lactose vehicle, caused a dose-related inhibition of antigen-induced bronchospasm ( Figure 5 ). The ID" values were RP 73401 7 ± 1 g kg-', rolipram 5 ±1 g kg'.
In the anaesthetized rat bronchospasm induced by antigen (ovalbumin, 1 mg, i.v.) challenge was inhibited in a dosedependent manner by RP 73401 (Figure 6 ). The calculated IDm was 100 ± 25 jig kg-'. Lactose alone had no significant effect on antigen-induced bronchospasm.
Antigen-induced cell influx
In guinea-pigs and rats, aerosolized antigen but not vehicle caused an increase in total cell and eosinophil numbers in PAF-induced bronchial hyperreactivity PAF infusion significantly increased bronchoconstrictor responses to bombesin from 18 ± 3% of maximum PIP (before PAF infusion) to 39± 2% of maximum PIP. This represented an increase of 179 ± 5% over the pre-infusion response. Infusion of PAF vehicle (0.1% BSA) had no significant effect. RP 73401 (0.02-100 gg kg-', i.v.) produced (n = 5-11) (Figure 8) . Maximum inhibition was achieved with the smallest dose of RP 73401 which could be given by this technique. Lactose alone had no significant effect on leakage.
Effects on salbutamol-induced bronchodilatation
Salbutamol (2 or 10lygkg-', i.t.) caused a dose-related inhibition of histamine-induced bronchospasm (Table 6) . When given 2min before salbutamol (2mgkg-') RP 73401 (4 and 401tgkg-') appeared to potentiate the effects of the P2-adrenoceptor agonist in terms of magnitude (Table 6 ).
With the higher dose of RP 73401 (40plgkg-') both the response magnitude and duration of action of salbutamol (2 mg kg-') were significantly increased. Combining the larger doses of salbutamol (10 jlg Baseline heart rate and mean arterial blood pressure in the anaesthetized rat were 426 ± 16 beats min-' an4 120 ± 2 mmHg respectively, n = 20. RP 73401 up to the top dose (0.25 mg kg-', i.v.) was without effect on heart rate whereas a small (14 ± 1%) fall, which was not dose-related, in mean arterial blood pressure was seen. This compares with the vehicle-induced fall of 6± 1%. The effect of RP 73401 was maximal within 5 min of dosing.
In the anaesthetized guinea-pig, baseline mean arterial blood pressure was 46 ± 3 mmHg. Baseline heart rate was 258 ± 6 beats min-'. When administered as a dry powder formulation into the airways at the IDM against histamineinduced bronchospasm (IDs: 34 ± 6 pg kg-'), RP 73401 (n = 6) had no significant effect on mean arterial blood pressure (% change: + 2 ± 2%) or heart rate (% change: + 3 ± 2%). ." E .y Ic >-0 Figure 7 The effects of RP 73401 on PAF-induced bronchial hyperreactivity (BHR) to bombesin in the anaesthetized guinea-pig.
Results are expressed as mean ± s.e.mean, n = 3-12. *P < 0.05 compared to vehicle control group.
Discussion
RP 73401 is a very selective inhibitor of the PDE IV isoenzyme compared with its effects on other PDE isoenzymes. RP 73401 inhibits the activity of PDE IV isoenzyme isolated from pig aorta or guinea-pig eosinophils with IC50 values of about 1 nM Ashton et al., 1994) . It is at least 19,000 fold more selective for the type IV than for type I, II, III or V Ashton et al., 1994; Souness et al., 1994b) . RP 73401 seems to interact with the PDE IV isoenzyme differently from rolipram since the potency of the latter depends on enzyme location, enzyme conformation and cell type Souness et al., 1994b) . The present study demonstrates potent antiinflammatory and bronchodilator effects of RP 73401 in guinea-pigs and rats. RP 73401 relaxed guinea-pig isolated tracheal preparations under basal tone or when precontracted by putative asthma mediators such as histamine, a muscarinic cholinoceptor agonist and LTD4 indicating that RP 73401 acts as a functional antagonist. Comparison with previously reported data in this preparation (Souness et al., 1994a) 73401 is less potent than the P2-adrenoceptor agonist salbutamol but considerably more potent than the non-selective PDE inhibitor theophylline (Karlsson & Persson, 1981) . All agents produced complete relaxations of the induced tone.
Consistent with the results in vitro, RP 73401 and rolipram each potently and dose-dependently inhibited bronchoconstriction induced by histamine, methacholine and LTD4 in anaesthetized guinea-pigs, the contractions produced by LTD4 being particularly sensitive (about 10 times more than the other spasmogens) to each of the PDE IV inhibitors. Furthermore, the duration of the inhibition of LTD4 with RP 73401 or rolipram was significantly longer than with the other spasmogens. The prolonged duration was not dependent on the magnitude of the inhibition indicating that it is the mechanism of LTD4-induced bronchospasm that is particularly sensitive to inhibition by the PDE inhibitors. Additionally in conscious animals, the bronchospasm produced by antigen aerosol (in the presence of a histamine (HI) receptor antagonist) was suppressed by prior treatment with RP 73401 or rolipram. Interestingly, RP 73401 was 5 to 9 times more potent as an inhibitor of this allergic contraction, than of those produced by histamine and methacholine, supporting the view that leukotrienes indeed are major mediators of this immediate response. It is possible that suppression of mediator release from inflammatory cells (see below), in addition to a direct smooth muscle relaxant effect, also contributed to inhibition of this allergic response. Acute, antigen-induced bronchospasm in the rat was similarly inhibited by pretreatment with RP 73401.
RP 73401 and rolipram were equipotent inhibitors of bronchospasm in the guinea-pig, despite a 1000 fold difference in potency on the type IV enzyme isolated from pig aortic smooth muscle or bovine trachea Souness et al., 1994b (Karlsson & Persson, 1981 ).
The present data on the functional importance of the type IV PDE in regulating airways tone is in general agreement with earlier studies by us and others (see review by . It is worth noting, though, that selective inhibitors of the type III PDE relax guinea-pig trachealis in vitro, but with a lower potency . Similarities between guinea-pig and human airways preparations in vitro regarding PDE isoenzyme profiles and relative functional importance (Qian et al., 1993; DeBoer et al., 1993) predict that RP 73401 will also relax human isolated airways preparations.
RP 73401 significantly reduced the influx of eosinophils into the airways following antigen exposure in sensitized guinea-pigs and rats. RP 73401 was however twice as potent as rolipram . PDE inhibitors may act in several ways to reduce cell trafficking into the airways (see review by Ashton et al., 1994) .
Plasma extravasation from postcapillary venules of the tracheobronchial microcirculation induced by histamine and other pro-inflammatory mediators, has been reported as a potent pro-inflammatory mechanism in human asthmatic airways (Persson, 1988) . These mediators may act directly to produce contraction of endothelial cells, a prerequisite for plasma extravasation. RP 73401 inhibited microvascular leakage in the guinea-pig which is in agreement with our earlier findings that PDE IV (rolipram) and PDE V (zaprinast) inhibition prevents PAF-induced MVL in the guineapig lung . Interestingly, RP 73401 was more potent in inhibiting leakage (this study) than rolipram (no effect at 50 lg, i.t., although PAF was used as the stimulus in the latter study. MVL into the airway lumen (lavage fluid) was more readily inhibited than into the tracheobronchial tissues which suggests that RP 73401 more effectively inhibits epithelial than endothelial membrane permeability, possibly as a consequence of PDE isoenzyme distribution. The PDE isoenzyme profile in the endothelium of the airway microvasculature is not known but, in bovine and porcine aorta, PDE II and IV predominate whereas PDE III may be important in the pulmonary artery (see (Nicholson & Shahid, 1994) . Indeed, whereas both type III and type IV PDE inhibitors have been shown to induce bronchodilatation in the dog, only the latter did not produce cardiovascular side-effects at doses which produced bronchodilatation (Heaslip et al., 1991) . In our study, RP 73401 did not cause significant changes in arterial blood pressure or heart rate when administered to anaesthetized rats or guinea-pigs at doses producing significant inhibition of bronchospasm. We have demonstrated that, following i.t. administration of RP 73401 (500 ftg kg-') to rats, peak plasma levels are reached after 5 min (97 ± 44 nM), remain high after 15 min (79 ± 40 nM) and thereafter decrease to 3 ± 1 nM after 6 h (data on file with Rhone-Poulenc Rorer Ltd.). This data demonstrates that, following i.t. administration, RP 73401 achieves a concentration in the systemic circulation which is greater than the IC50 for inhibition of PDE type IV. The lack of cardiovascular effects in our studies would therefore seem to be due to tissue PDE subtype selectivity rather than low systemic availability. Thus, specific type IV PDE inhibitors such as RP 73401 may be more selective and useful for the treatment of asthma than specific type III inhibitors or mixed type III/IV inhibitors. Furthermore, PDE III inhibitors such as siguazodan have no effect on airways MVL and only poorly inhibit antigen-induced cell influx into BAL fluid .
Asthma is an inflammatory disease of the airways where the prominent symptoms are a reversible airflow obstruction combined with an increased responsiveness to non-specific bronchoconstrictor stimuli. Inflammatory changes in the asthmatic airway include microvascular plasma protein leakage and oedema, mucous gland hyperplasia, smooth muscle hypertrophy, sub-epithelial fibrosis, lumenal mucus and cellular debris, leukocyte (predominantly eosinophils) infiltration of the bronchial mucosa and epithelial cell damage and/or sloughing (Djukanovic et al., 1990; Alexander et al., 1991) . Release of mast cell mediators such as histamine and possibly leukotrienes plays an important role in immediate bronchoconstriction; eosinophils, macrophages, lymphocytes and other inflammatory cells are more usually associated with late phase events and chronic disease (Djukanovic et al., 1990; Alexander et al., 1991) .
Glucocorticosteroids are currently the most effective drugs available to treat airway inflammation. The number and activity 'of infiltrating inflammatory cells, particularly eosinophils, are reduced and microvascular leakage (and thereby oedema) and other signs of the inflammatory response are dampened (Barnes & Pedersen, 1993) . Glucocorticosteroids do not however inhibit the release of mast cell mediators, have no direct bronchodilator activity and, when given for prolonged periods, are associated with significant systemic adverse effects (Barnes & Pedersen, 1993) . A drug with combined anti-inflammatory and bronchodilator actions would therefore provide additional benefits in the treatment of asthma. The in vitro and in vivo studies described here demonstrate RP 73401 to possess many of these desirable actions at least in animal models of allergic inflammation.
In conclusion, RP 73401 has bronchodilator activity and is a functional antagonist of the bronchoconstriction produced by asthma mediators. More importantly, its potent antiinflammatory actions reduce those facets of allergic pulmonary inflammation in the guinea-pig and rat which are characteristic of human asthma. Its potency and selectivity make RP 73401 an ideal tool to investigate the functional importance of the PDE IV isoenzyme in biological systems. RP 73401 is a promising new agent for the treatment of asthma and other inflammatory disease of human airways.
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